NASDAQ:AVRO

AVROBIO - AVRO Stock Forecast, Price & News

$0.66

+0.02 (+3.13%)

(As of 10/4/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.64
▼
$0.68
50-Day Range: $0.64
▼
$1.11
52-Week Range: $0.63
▼
$6.62

Volume: 360,820 shs
Average Volume: 528,158 shs
Market Capitalization: $28.86 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.29

AVROBIO MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 701.6% Upside
$5.29 Price Target
Short Interest: Healthy
0.79% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.15) to ($1.64) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

487th out of 1,087 stocks

Biological Products, Except Diagnostic Industry

75th out of 169 stocks

3.3

Analyst's Opinion

Consensus Rating
AVROBIO has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.29, AVROBIO has a forecasted upside of 701.6% from its current price of $0.66.
Amount of Analyst Coverage
AVROBIO has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.79% of the float of AVROBIO has been sold short.
Short Interest Ratio / Days to Cover
AVROBIO has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in AVROBIO has recently increased by 13.39%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
AVROBIO does not currently pay a dividend.
Dividend Growth
AVROBIO does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AVRO.

2.0

News and Social Media Coverage

News Sentiment
AVROBIO has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for AVROBIO this week, compared to 2 articles on an average week.
Search Interest
2 people have searched for AVRO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added AVROBIO to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AVROBIO insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.40% of the stock of AVROBIO is held by insiders.
Percentage Held by Institutions
62.14% of the stock of AVROBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for AVROBIO are expected to grow in the coming year, from ($2.15) to ($1.64) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AVROBIO is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AVROBIO is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AVROBIO has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About AVROBIO (NASDAQ:AVRO) Stock

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Receive AVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter.

AVRO Stock News Headlines

September 27, 2022 | businesswire.com

AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress - Business Wire

September 27, 2022 | finance.yahoo.com

AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress

September 20, 2022 | benzinga.com

AVROBIO Receives Rare Pediatric Disease Designation From FDA For First Gene Therapy In Development For Cy - Benzinga

September 20, 2022 | businesswire.com

AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis - Business Wire

September 20, 2022 | finance.yahoo.com

AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis

September 14, 2022 | businesswire.com

AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial - Business Wire

September 14, 2022 | finance.yahoo.com

August 31, 2022 | businesswire.com

AVROBIO to Participate in Four Upcoming Investor Conferences in September - Business Wire

August 31, 2022 | finance.yahoo.com

AVROBIO to Participate in Four Upcoming Investor Conferences in September

August 29, 2022 | reuters.com

AVRO.O - Avrobio Inc | Stock Price & Latest News | Reuters

August 28, 2022 | fool.com

Avrobio, Inc. (NASDAQ: AVRO)

August 17, 2022 | businesswire.com

Sonoma Biotherapeutics Expands Board of Directors with Appointments of Katina Dorton, J.D., MBA, and John Davis, M.D., MPH - Business Wire

August 17, 2022 | finance.yahoo.com

Global Gaucher Disease Treatment Market to Grow at ~5% CAGR during 2022-2031; Market to Expand Owing to Worldwide Prevalence of Gaucher Disease, Rapid R&D Progress, and Government Actions for Therapeutic Advances– Kenneth Research - Yahoo Finance

August 17, 2022 | globenewswire.com

August 9, 2022 | benzinga.com

Recap: Avrobio Q2 Earnings - Benzinga

August 9, 2022 | businesswire.com

AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update - Business Wire

August 9, 2022 | msn.com

Recap: Avrobio Q2 Earnings

August 4, 2022 | finance.yahoo.com

Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights - Yahoo Finance

August 1, 2022 | businesswire.com

AVROBIO to Participate in Two Upcoming Investor Conferences in August - Business Wire

August 1, 2022 | finance.yahoo.com

AVROBIO to Participate in Two Upcoming Investor Conferences in August

July 13, 2022 | benzinga.com

AVROBIO Receives Orphan Drug Designation From The US FDA For AVR-RD-05, A Gene Therapy For Mucopolysaccharidosis Type II Or Hunter Syndrome - Benzinga

July 13, 2022 | benzinga.com

AVROBIO Receives Orphan Drug Designation from the US Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome - Benzinga

July 13, 2022 | finance.yahoo.com

AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome

June 16, 2022 | seekingalpha.com

BioLineRx hires Avrobio exec as chief commercial officer to bolster cancer therapy efforts - Seeking Alpha

June 11, 2022 | seekingalpha.com

With bluebird bio's success, what are other gene therapies companies to pay attention to? - Seeking Alpha

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter.

AVRO Company Calendar

Last Earnings: 8/09/2022
Today: 10/04/2022
Next Earnings (Estimated): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AVRO
CUSIP: N/A
CIK: 1681087
Web: www.avrobio.com
Phone: (617) 914-8420
Fax: N/A
Employees: 122
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $5.29
High Stock Price Forecast: $8.00
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +701.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.72)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-119,130,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -76.04%
Return on Assets: -64.01%

Debt

Debt-to-Equity Ratio: 0.13
Current Ratio: 11.11
Quick Ratio: 11.11

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.88 per share
Price / Book: 0.17

Miscellaneous

Outstanding Shares: 43,774,000
Free Float: 40,972,000
Market Cap: $28.86 million
Optionable: Not Optionable
Beta: 1.59

Key Executives

Mr. Geoff MacKay BSc (Age 56)
Co- Founder, Pres, CEO & Director
Comp: $754.39k

Mr. Erik John Ostrowski M.B.A. (Age 49)
CFO & Treasurer
Comp: $554.66k

Mr. Jeffrey Medin Ph.D.
Scientific Founder

Mr. Matthew Arnold
Head of Operations

Mr. Steven N. Avruch J.D. (Age 61)
Chief Legal Officer & Sec.

Ms. Monique Da Silva
Sr. VP of Corp. Communications

Ms. Deanna M. Petersen MBA (Age 60)
Chief Bus. Officer

Ms. Azadeh Golipour Ph.D.
Chief Technology Officer

Mr. Andreas Kouri
Sr. VP of Global Supply Chain & External Manufacturing

Dr. Essra Ridha FFPM
M.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AVRO Stock - Frequently Asked Questions

Should I buy or sell AVROBIO stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVROBIO in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AVRO shares.
View AVRO analyst ratings or view top-rated stocks.
What is AVROBIO's stock price forecast for 2022?: 6 analysts have issued 12 month price objectives for AVROBIO's stock. Their AVRO share price forecasts range from $3.00 to $8.00. On average, they predict the company's share price to reach $5.29 in the next twelve months. This suggests a possible upside of 732.3% from the stock's current price.
View analysts price targets for AVRO or view top-rated stocks among Wall Street analysts.
How have AVRO shares performed in 2022?: AVROBIO's stock was trading at $3.85 at the start of the year. Since then, AVRO shares have decreased by 83.5% and is now trading at $0.6351.
View the best growth stocks for 2022 here.
When is AVROBIO's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our AVRO earnings forecast.
How were AVROBIO's earnings last quarter?: AVROBIO, Inc. (NASDAQ:AVRO) posted its quarterly earnings data on Tuesday, August, 9th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by $0.10.
What other stocks do shareholders of AVROBIO own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AVROBIO investors own include Sorrento Therapeutics (SRNE), ImmunoGen (imgn), Aduro Biotech (ADRO), Aldeyra Therapeutics (ALDX), Amarin (AMRN), Biohaven Pharmaceutical (BHVN), Nabriva Therapeutics (NBRV), Selecta Biosciences (SELB), VBI Vaccines (vbiv) and Arbutus Biopharma (ABUS).

When did AVROBIO IPO?: (AVRO) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush Securities was co-manager.
What is AVROBIO's stock symbol?: AVROBIO trades on the NASDAQ under the ticker symbol "AVRO."
How do I buy shares of AVROBIO?: Shares of AVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is AVROBIO's stock price today?: One share of AVRO stock can currently be purchased for approximately $0.64.
How much money does AVROBIO make?: AVROBIO (NASDAQ:AVRO) has a market capitalization of $27.80 million. The company earns $-119,130,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis.
How many employees does AVROBIO have?: The company employs 122 workers across the globe.
How can I contact AVROBIO?: AVROBIO's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The official website for the company is www.avrobio.com. The company can be reached via phone at (617) 914-8420 or via email at ir@ampliphibio.com.

This page (NASDAQ:AVRO) was last updated on 10/4/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

AVROBIO - AVRO Stock Forecast, Price & News

AVROBIO MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows